Strategic Acquisition The recent acquisition by Jabil Inc. positions Pii as a part of a global engineering and manufacturing powerhouse, opening avenues for cross-selling comprehensive supply chain solutions and expanded service offerings to existing clients.

Innovative Platforms The launch of the Accelevate Early Development Platform demonstrates Pii's commitment to accelerating drug development timelines, providing sales opportunities with mid-sized and emerging pharmaceutical companies seeking faster IND readiness.

Investment in Capabilities Recent investments of $3.6 million in advanced filling, labeling, and inspection technologies highlight Pii's focus on expanding high-value aseptic and ISO-capable manufacturing services, appealing to clients with demanding quality and scalability needs.

Market Recognition Being recognized as a trusted partner for top global brands enhances Pii’s credibility and offers prospects opportunities through targeted outreach to high-profile pharmaceutical companies seeking reliable CDMO partners.

Evolving Data Security Despite recent data breach challenges, ongoing improvements in data security protocols present an opportunity to position Pii as a responsible and secure partner for sensitive pharmaceutical development projects, building trust with prospective clients concerned about compliance and PII protection.